What is Raynaud’s phenomenon? Raynaud’s phenomenon is a condition that affects your blood vessels. If you have Raynaud’s phenomenon, you have periods of time called “attacks” when your body does not send enough blood to the hands and feet. Attacks usually happen when you are cold or feeling stressed. During an attack, your fingers and toes may feel very cold or numb. Raynaud’s phenomenon is also called Raynaud’s disease or Raynaud’s syndrome.
¿Qué es el fenómeno de Raynaud? El fenómeno de Raynaud es una enfermedad que afecta los vasos sanguíneos. Si usted tiene el fenómeno de Raynaud, tiene periodos llamados "episodios" cuando el cuerpo no envía suficiente sangre a las manos y los pies. Los episodios generalmente ocurren cuando la persona tiene frío o se siente estresada. Durante un episodio, los dedos de las manos y los pies pueden sentirse muy fríos o entumecidos. El fenómeno de Raynaud también se conoce como la enfermedad de Raynaud o el síndrome de Raynaud.
What is acne? Acne is a common skin condition that happens when hair follicles under the skin become clogged. Oil and dead skin cells plug the pores, and outbreaks of lesions (often called pimples or zits) can happen. Most often, the outbreaks occur on the face but can also appear on the back, chest, and shoulders. For most people, acne tends to go away by the time they reach their thirties, but some people in their forties and fifties continue to have this skin problem.
What is scoliosis? Scoliosis is a sideways curve of the spine. Children and teens with scoliosis have an abnormal S-shaped or C-shaped curve of the spine. The curve can happen on either side of the spine and in different places in the spine. With treatment, observation, and follow-up with the doctor, most children and teens with scoliosis have normal, active lives.
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.